高危黑色素瘤切除术后辅助贝伐珠单抗的生存分析:AVAST-M试验
AVAST-M试验将1343例切除后的AJCC IIB、IIC和III期皮肤黑色素瘤患者随机分配至辅助贝伐珠单抗(7.5 mg/kg 每3周 共1年)或标准观察组,主要终点为5年总生存率(OS)的8%差异。中位随访6.4年,两组5年OS均为64%(HR 0.98, 95%CI 0.82-1.16, P=0.78),贝伐珠单抗组无病生存率51% vs 观察组45%(HR 0.85, 95%CI 0.74-0.99, P=0.03),但无远处转移生存率无显著差异。结论:辅助贝伐珠单抗改善无病间隔但不改善总生存。
要点
- 辅助贝伐珠单抗未改善高危黑色素瘤患者的5年总生存(64% vs 64%,HR 0.98,P=0.78)。
- 贝伐珠单抗组5年无病生存率显著优于观察组(51% vs 45%,HR 0.85,P=0.03)。
- BRAF突变状态可能预测未治疗时总生存较差及贝伐珠单抗潜在获益。
核心结论
- 高危黑色素瘤切除后辅助贝伐珠单抗改善无病间隔,但不改善总生存。
- BRAF突变状态可能预测未治疗时总生存较差及贝伐珠单抗潜在获益。
研究设计与样本
- 随机对照试验,纳入1343例切除后的AJCC IIB、IIC和III期皮肤黑色素瘤患者,随机接受辅助贝伐珠单抗(7.5 mg/kg 静脉注射 每3周 共1年)或标准观察。
- 主要终点为5年总生存率检测8%差异;次要终点包括无病间隔和远处无转移间隔;分析肿瘤和血液的预后及预测标志物。
主要发现
- 中位随访6.4年,515例(38%)死亡[贝伐珠单抗组254例(38%);观察组261例(39%)];707例(53%)复发[贝伐珠单抗组336例(50%),观察组371例(55%)]。
- 5年总生存率两组均为64%(HR 0.98;95%CI 0.82-1.16,P=0.78)。
- 5年无病生存率贝伐珠单抗组51% vs 观察组45%(HR 0.85;95%CI 0.74-0.99,P=0.03)。
- 5年无远处转移生存率贝伐珠单抗组58% vs 观察组54%(HR 0.91;95%CI 0.78-1.07,P=0.25)。
关键数值与推荐
- 5年总生存率:贝伐珠单抗组64% vs 观察组64%(HR 0.98;95%CI 0.82-1.16,P=0.78)。
- 5年无病生存率:贝伐珠单抗组51% vs 观察组45%(HR 0.85;95%CI 0.74-0.99,P=0.03)。
- 5年无远处转移生存率:贝伐珠单抗组58% vs 观察组54%(HR 0.91;95%CI 0.78-1.07,P=0.25)。
临床怎么用
- 不推荐在高危黑色素瘤切除后常规使用辅助贝伐珠单抗以改善总生存。
- 贝伐珠单抗可能改善无病间隔,但需权衡获益与毒性。
- BRAF突变状态可能作为预后和预测标志物,但需进一步验证。
局限性
- 主要终点未达到,总生存无改善。
- BRAF突变亚组分析为探索性,样本量有限。
- 中位随访6.4年,长期生存影响未知。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: Bevacizumab is a recombinant humanised monoclonal antibody to vascular endothelial growth factor shown to improve survival in advanced solid cancers. We evaluated the role of adjuvant bevacizumab in melanoma patients at high risk of recurrence. PATIENTS AND METHODS: Patients with resected AJCC stage IIB, IIC and III cutaneous melanoma were randomised to receive either adjuvant bevacizumab (7.5 mg/kg i.v. 3 weekly for 1 year) or standard observation. The primary end point was detection of an 8% difference in 5-year overall survival (OS) rate; secondary end points included disease-free interval (DFI) and distant metastasis-free interval (DMFI). Tumour and blood were analysed for prognostic and predictive markers. RESULTS: Patients (n=1343) recruited between 2007 and 2012 were predominantly stage III (73%), with median age 56 years (range 18-88 years). With 6.4-year median follow-up, 515 (38%) patients had died [254 (38%) bevacizumab; 261 (39%) observation]; 707 (53%) patients had disease recurrence [336 (50%) bevacizumab, 371 (55%) observation]. OS at 5 years was 64% for both groups [hazard ratio (HR) 0.98; 95% confidence interval (CI) 0.82-1.16, P = 0.78). At 5 years, 51% were disease free on bevacizumab versus 45% on observation (HR 0.85; 95% CI 0.74-0.99, P = 0.03), 58% were distant metastasis free on bevacizumab versus 54% on observation (HR 0.91; 95% CI 0.78-1.07, P = 0.25). Forty four percent of 682 melanomas assessed had a BRAFV600 mutation. In the observation arm, BRAF mutant patients had a trend towards poorer OS compared with BRAF wild-type patients (P = 0.06). BRAF mutation positivity trended towards better OS with bevacizumab (P = 0.21). CONCLUSIONS: Adjuvant bevacizumab after resection of high-risk melanoma improves DFI, but not OS. BRAF mutation status may predict for poorer OS untreated and potential benefit from bevacizumab. CLINICAL TRIAL INFORMATION: ISRCTN 81261306; EudraCT Number: 2006-005505-64.
引用
- Corrie PG, Marshall A, Nathan PD, et al. Adjuvant bevacizumab for melanoma patients at high risk of recurrence: survival analysis of the AVAST-M trial. Ann Oncol. 2018. PMID: 30010756. doi:10.1093/annonc/mdy229
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。